A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma

Overview of attention for article published in OncoTargets and therapy, November 2020

Altmetric Badge

Mentioned by

twitter: 1 X user

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 7 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 1 X users, with an upper bound of 792 followers.

A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free ... https://t.co/ZXkHVhsNN3

07 Dec 2021

Reply Repost Favourite

A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free ... https://t.co/ZXkHVhsNN3

06 Dec 2021

Reply Repost Favourite

A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free ... https://t.co/ZXkHVhsNN3

23 Apr 2021

Reply Repost Favourite

A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma https://t.co/ZXkHVhsNN3

04 Mar 2021

Reply Repost Favourite

Dove Medical Press

Article Metrics

A Novel ROS1-FBXL17 Fusion Co-Existing with CD74-ROS1 Fusion May Improve Sensitivity to Crizotinib and Prolong Progression-Free Survival of Patients with Lung Adenocarcinoma

Mentioned by

Citations

Readers on